- Details
- Muhieddine Labban and Quoc-Dien Trinh discuss transportation barriers in prostate cancer care in Massachusetts. Their work reveals significant transportation disparities affecting Black patients, who are three to four times more likely to use public transportation for healthcare visits and spend substantially more time commuting. Despite Massachusetts having the fifth-largest transportation system...
|
- Details
- Andrea Miyahira speaks with Ece Eksi about a publication examining spatial organization of AR-positive cells in the prostate tumor microenvironment. Using multiplex imaging with 32 protein markers, Dr. Eksi's team identifies 27 distinct cell types and reveals that cellular neighborhoods in prostate tumors are primarily driven by androgen receptor expression in the stroma. The study uncovers new in...
|
- Details
- Mindy Graham discusses findings from her research on MYC-driven prostate cancer, recently published in Nature Communications. Using single-cell RNA sequencing and immunostaining, Dr. Graham's team reveals how MYC activation drives consistent changes in the tumor microenvironment across both human and mouse models of prostate cancer. The research demonstrates a surprising transition from an initial...
|
- Details
- Roni Haas joins Andrea Miyahira to discuss research on prostate cancer radioresistance, focusing on differences between conventional and hypofractionated radiation therapy approaches. The study reveals that conventional radiation treatment, involving multiple small doses over time, leads to a more aggressive radioresistant phenotype with greater mutations and driver gene dysregulation compared to...
|
- Details
- Andrea Miyahira interviews Timothy Rebbeck about his research group's Nature Genetics paper examining prostate cancer genetic susceptibility in sub-Saharan Africa. The study analyzes approximately 7,000 individuals across African centers, revealing significant genetic heterogeneity in prostate cancer risk both within Africa and between African and non-African populations. Dr. Rebbeck discusses the...
|
- Details
- Ruchika Talwar interviews David Morris about changes in 2025 for Medicare Part D resulting from the Inflation Reduction Act (IRA). Dr. Morris discusses how these changes benefit prostate cancer patients and all Medicare recipients who have Medicare Part D coverage. This Medicare change reduces the out-of-pocket expenses for prescription drugs paid by Part D plans. Key points include the introducti...
|
- Details
- Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. Biographies: Jason Hafron, MD, CMO, Oncologist, Director of Research, Michigan I...
|
- Details
- Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...
|
- Details
- Defining optimal therapeutic sequencing strategies in prostate cancer (PC) is challenging and may be assisted by artificial intelligence (AI)-based tools for an analysis of the medical literature. To demonstrate that INSIDE PC can help clinicians query the literature on therapeutic sequencing in PC and to develop previously unestablished practices for evaluating the outputs of AI-based support pla...
|
- Details
- Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
|
